The €8.7 million series B will support studies targeting two bacterial infections and the creation of a drug manufacturing unit.

Describing a country as a ‘shithole’ isn’t going to endear you to anyone, but President Trump’s latest alleged outburst has struck a nerve with one particular…

Tyagi joins Hikma with a brief to stimulate noninjectable R&D activity at a time when the company's generic drug unit is suffering.

The German company is seeking $22 million to support a clutch of clinical trials designed to expand use of Ameluz in types of skin cancer.

The setback leaves Concert committed to taking the drug forward in alopecia areata but uncertain of its future beyond the indication.

Novartis poached Pfizer oncology head Liz Barrett, Ed Kaye became Stoke Therapeutics' CEO, and Perrigo hired Uwe Röhrhoff as CEO.

Roche joins Merck KGaA as pharma parter for Forty Seven's CD47-targeting antibody, which blocks a "don't eat me" signal sent out by…

NIH scientists have modeled the 3D structure of DHHC enzymes, which modify EGFRs, which are implicated in a range of cancers.

The panel felt Aradigm failed to show evidence of the safety and efficacy of Linhaliq in delaying the first exacerbation in chronic lung infections.